<?xml version='1.0' encoding='utf-8'?>
<document id="21768274"><sentence text="How current understanding of clearance mechanisms and pharmacodynamics of therapeutic proteins can be applied for evaluation of their drug-drug interaction potential." /><sentence text="Increasing use of therapeutic proteins (TPs) in polypharmacy settings calls for more in-depth understanding of the biological interactions that can lead to increased toxicity or loss of pharmacological effect" /><sentence text=" Factors such as patient population, medications that are likely to be coadministered in that population, clearance mechanisms of a TP, and concomitant drugs have to be taken into account to determine the potential for drug-drug interactions (DDIs)" /><sentence text=" The most well documented TP DDI mechanism involves cytokine-mediated changes in drug-metabolizing enzymes" /><sentence text=" Because of the limitations of the current preclinical models for addressing this type of DDI, clinical evaluation is currently the most reliable approach" /><sentence text=" Other DDI mechanisms need to be addressed on a case-by-case basis" /><sentence text=" These include altered clearance of TPs resulting from the changes in the target protein levels by the concomitant medication, displacement of TPs from binding proteins, modulation of FcÎ³ receptor expression, and others" /><sentence text=" The purpose of this review is to introduce the approach used by Pfizer scientists for evaluation of the DDI potential of novel TP products during drug discovery and development" /><sentence text="" /></document>